Application of Epigallocatechin gallate (EGCG) in anti-tumor medicine

A technology of epigallocatechin and gallate, applied in the field of epigallocatechin gallate, can solve problems such as undeveloped success, achieve good application prospects, improve sensitivity, and enhance the effect of effect

Inactive Publication Date: 2003-10-01
EAST CHINA UNIV OF SCI & TECH
View PDF0 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As a clinically applied MDR reversal agent, drugs have not been successfully developed so far

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Epigallocatechin gallate (EGCG) in anti-tumor medicine
  • Application of Epigallocatechin gallate (EGCG) in anti-tumor medicine
  • Application of Epigallocatechin gallate (EGCG) in anti-tumor medicine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0016] Cytotoxic effects of EGCG on MDR cells (KB-A-1) and drug-sensitive cells (KB-3-1).

[0017] EGCG was purchased from Sigma, and diluted to the required concentration with DMEM culture medium. The cytotoxic effect of EGCG on MDR cells (KB-A-1) and drug-sensitive cells (KB-3-1) was determined by thiazolium blue (MTT) rapid colorimetric method. Cells in logarithmic growth phase 10 4 cell ml -1 Inoculate in a 96-well culture plate, 0.2ml per well, add a certain concentration of TP and EGCG respectively, parallel 4 wells for each concentration, add an equal volume of culture medium to the control group, and place at 37°C, 5% CO 2 Incubate in an incubator with saturated humidity for 1-4 days, add 5mg·ml to each well 4 hours before the end of the experiment -1 MTT 10 μl, add 0.04N DMSO (dimethyl sulfoxide) to each well after the culture, 150 μl per well, shake for 10 minutes, the MTT reduction product is completely dissolved, use a BioRad550 microplate reader, use 550nm as ...

Embodiment 2

[0045] Comparison of drug resistance multiples between EGCG and traditional tumor chemotherapy drugs.

[0046] Adopt MTT method (referring to embodiment 1 for specific experimental operation) to investigate three kinds of anticancer drugs doxorubicin, colchicine and vinblastine that are more commonly used clinically under different concentrations and certain action time (three days) on KB-3-1 and the cytotoxicity of KB-A-1, plotting the different concentrations of the drug and the survival rate of the cells, determining the half inhibitory concentration of the cells, and calculating the resistance factor (RF=IC50(KB-A-1) / IC50 (KB-3-1)), and compared EGCG with the drug resistance multiples of these three traditional tumor chemotherapy drugs under the same action time. See the experimental results image 3 , Figure 4 , Figure 5 and the following table:

[0047] Table 3 Comparison of resistance multiples between EGCG and traditional tumor chemotherapy drugs

[0048] I...

Embodiment 3

[0054] Effect of EGCG on the anticancer effect of doxorubicin:

[0055] Cells in logarithmic growth phase 10 4 cell ml -1 Inoculate in 96-well culture plate, 0.2ml per well, first add 40μg / ml 10μg / ml EGCG to treat, then add doxorubicin, the concentration range is 0-32μg / ml, parallel 4 wells in each group, add the same amount to the control group volume of culture medium, placed at 37°C, 5% CO 2 and saturated humidity incubator for 3 days, add 5 mg·ml to each well 4 hours before the end of the experiment -1 MTT 10μl, add 0.04N DMSO (dimethyl sulfoxide) to each hole after the culture, 150μl per hole, shake for 10min, the MTT reduction product is completely dissolved, use BioRad 550 microplate reader, use 550nm as the experimental wavelength, 655nm as the experimental wavelength Measure the absorbance with reference to the wavelength, calculate the half inhibitory concentration (IC50), and calculate the reversal factor (reversal index.RI). See the experimental results Figu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An application of (-)-epigallocatechin gellate (EGCG) extracted from tea in preparing the medicines for treating tumor is disclosed, which features that said EGCG can be used as sensitizer and synergistic of antineoplastic medicine.

Description

technical field [0001] The present invention relates to the use of epigallocatechin gallate. technical background [0002] Multidrug resistance (MDR) refers to the generation of cross-resistance to multiple antitumor drugs with different structures and mechanisms of action when cancer cells are exposed to one antitumor drug and develop drug resistance. Cancer patients often develop multidrug resistance after chemotherapy. Multidrug resistance is the main reason for the failure of cancer chemotherapy, and it is also one of the problems that need to be solved urgently in cancer chemotherapy. The formation mechanism of multidrug resistance is complex. Tumor cells can lead to the production of MDR through different ways, and at the same time, a single MDR cell can have multiple drug resistance mechanisms at the same time. Any combination of one or more mechanisms can lead to MDR. [0003] Combination of MDR reversal agents and anticancer drugs will greatly improve the curati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/353A61P35/00
Inventor 魏东芝刘建文梅郁盈
Owner EAST CHINA UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap